NuVasive(R) to Participate in Investor Events in August and September 2014

SAN DIEGO, CA--(Marketwired - Aug 5, 2014) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that management will participate in the following investor events in August and September 2014:

• The Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston, Massachusetts, on Wednesday, August 13, 2014, at 11:00 am ET
  
  
• The William Blair West Coast Med Tech and Diagnostic Field Trip at NuVasive's Headquarters in San Diego, California on Tuesday, August 26, 2014, at 11:45 am PT
  
  
• The Piper Jaffray So Cal Med Tech Bus Tour at NuVasive's Headquarters in San Diego, California on Wednesday, August 27, 2014, at 12:00 pm PT
  
  
• The Baird 2014 Health Care Conference at the Palace Hotel in New York City, New York, on Thursday, September 4, 2014, at 12:15 pm ET
  
  

A live webcast of each of the presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, a replay of each presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine.

As the 3^rd largest player in the $8.7 billion global spine market, NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery (or MAS^®) platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully-integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion with our groundbreaking XLIF^® procedures, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company has developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally as it continues to expand its international footprint and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation^®, and Absolute Responsiveness^®.

NuVasive cautions you that statements included in this press release or by management when participating in the above-described investor events that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact

Media Contact:
Margie Elsesser
NuVasive, Inc.
858-638-5516
Email Contact